Recent Decision in FCA Case Has Key Implications for Labs
The decision deepens a split among circuit courts regarding how to determine liability for false claims
The decision deepens a split among circuit courts regarding how to determine liability for false claims
Recent enforcement actions involved usual targets such as COVID-19, genetic, and urine drug testing, but EKRA also made an appearance
Recent DOJ settlements continue to focus on issues involving medical necessity and marketer compensation
COVID-19-related schemes dominated recent enforcement efforts, which include a national healthcare fraud enforcement action
Genetic testing related fraud was a theme in recent enforcement actions involving medical laboratories and lab testing
Examining DOJ and OIG investigations of labs and their owners: Recent cases show continued focus on the usual enforcement targets.
Recent enforcement actions and court cases include kickback schemes a-plenty and a reminder to focus on HIPAA compliance
Recent enforcement actions include convictions and guilty pleas for false claims-related allegations involving toxicology labs.
Recent cases show labs should be wary of issues such as improper relationships, medical necessity, kickbacks, and potential telehealth fraud.
Recent cases involve Medicare’s 14-Day Rule, improper PHI disclosure to a media outlet, kickbacks, and COVID-19 fraud.
A settlement for kickback allegations, prison time for lab owners convicted of COVID-19 fraud, and 10x Genomics gets OK for lawsuit.